CorMedix Inc. Files 8-K on Financials
Ticker: CRMD · Form: 8-K · Filed: Oct 20, 2025 · CIK: 1410098
| Field | Detail |
|---|---|
| Company | Cormedix Inc. (CRMD) |
| Form Type | 8-K |
| Filed Date | Oct 20, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-k
TL;DR
CorMedix filed an 8-K on Oct 20, 2025, updating financials. Check it out.
AI Summary
CorMedix Inc. filed an 8-K on October 20, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, with the company's principal executive offices located at 300 Connell Drive, Suite 4200, Berkeley Heights, New Jersey.
Why It Matters
This 8-K filing provides an update on CorMedix Inc.'s financial performance and condition, which is crucial for investors to assess the company's health and future prospects.
Risk Assessment
Risk Level: low — This filing is a routine 8-K reporting financial information and does not appear to contain any significant new risks or material adverse events.
Key Players & Entities
- CorMedix Inc. (company) — Registrant
- October 20, 2025 (date) — Date of earliest event reported
- 300 Connell Drive, Suite 4200 Berkeley Heights, New Jersey 07922 (address) — Principal Executive Offices
FAQ
What specific financial information is being reported in this 8-K filing?
The filing indicates it pertains to 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits'.
When was the earliest event reported in this filing?
The earliest event reported was on October 20, 2025.
What is the principal executive office address for CorMedix Inc.?
The principal executive offices are located at 300 Connell Drive, Suite 4200, Berkeley Heights, New Jersey 07922.
What is the company's telephone number?
The registrant's telephone number, including area code, is (908) 517-9500.
What is the SIC code for CorMedix Inc.?
The Standard Industrial Classification code for CorMedix Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 541 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2025-10-20 08:10:42
Key Financial Figures
- $0.001 — ge on which registered) Common Stock, $0.001 Par Value CRMD Nasdaq Global Market
Filing Documents
- ea0261760-8k_cormedix.htm (8-K) — 25KB
- ea026176001ex99-1_cormedix.htm (EX-99.1) — 17KB
- ex99-1_001.jpg (GRAPHIC) — 15KB
- 0001213900-25-100156.txt ( ) — 230KB
- crmd-20251020.xsd (EX-101.SCH) — 3KB
- crmd-20251020_lab.xml (EX-101.LAB) — 33KB
- crmd-20251020_pre.xml (EX-101.PRE) — 22KB
- ea0261760-8k_cormedix_htm.xml (XML) — 4KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On October 20, 2025, CorMedix Inc. (the "Company") issued a press release announcing its preliminary financial results for the quarter ended September 30, 2025. The preliminary results are subject to the completion of accounting procedures and are therefore subject to adjustment. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The information in this Item 2.02, including the press release attached hereto as Exhibit 99.1, is intended to be furnished under Item 2.02 and Item 9.01 of Form 8-K and shall be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, and shall be deemed incorporated by reference into any filing by the Company under the Securities Act of 1933, as amended (the "Securities Act"), and the Exchange Act.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release issued by CorMedix Inc., dated October 20, 2025. 104 Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL). - 1 -
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 20, 2025 CORMEDIX INC. By: /s/ Joseph Todisco Joseph Todisco Chief Executive Officer - 2 -